|
Malignant neoplasm of prostate
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Several SNPs (SRD5A1 rs3822430, SRD5A2 rs2300700, CYP3A43 rs800672, and CYP19 rs700519; Ptrend < .05) were significantly associated with both circulating hormone levels and prostate cancer risk.
|
27164191 |
2016 |
|
Malignant neoplasm of prostate
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
CYP3A43 and PARP2 variants have been shown to occur in other familial PCs and our findings add to the contribution that these variants potentially have in the risk and development of PC in BRCAX cases.
|
26585945 |
2016 |
|
Malignant neoplasm of prostate
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
|
25337833 |
2015 |
|
Malignant neoplasm of prostate
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Four missense variants, BLM Gln123Arg, PARP2 Arg283Gln, LRCC46 Ala295Thr and KIF2B Pro91Leu, and one nonsense variant, CYP3A43 Arg441Ter, showed complete co-segregation with PCa status.
|
25111073 |
2014 |
|
Malignant neoplasm of prostate
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
However, carriers of the CYP3A43 G-allele showed a significant 5-fold increase in mortality among early onset diagnosed prostate cancers.
|
20621111 |
2010 |
|
Malignant neoplasm of prostate
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the CYP3A43-Pro(340)Ala polymorphism contributes to prostate cancer risk.
|
15894682 |
2005 |
|
Malignant neoplasm of prostate
|
0.370 |
Biomarker
|
disease |
CTD_human |
Our results suggest that the CYP3A43-Pro(340)Ala polymorphism contributes to prostate cancer risk.
|
15894682 |
2005 |
|
Malignant neoplasm of prostate
|
0.370 |
Biomarker
|
disease |
BEFREE |
CYP3A43*3 was associated with family history-positive prostate cancer (age- and race-adjusted odds ratio = 5.86, 95% confidence interval, 1.10-31.16).
|
15548719 |
2004 |
|
Prostatic Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians.
|
15894682 |
2005 |
|
Prostatic Neoplasms
|
0.310 |
GeneticVariation
|
group |
LHGDN |
CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians.
|
15894682 |
2005 |
|
Nephrosis
|
0.200 |
Biomarker
|
disease |
CTD_rat |
Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model.
|
18725544 |
2008 |
|
Nephrosis
|
0.200 |
Biomarker
|
disease |
RGD |
Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model.
|
18725544 |
2008 |
|
Dehydroepiandrosterone sulfate measurement (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic Association Study of Eight Steroid Hormones and Implications for Sexual Dimorphism of Coronary Artery Disease.
|
31169883 |
2019 |
|
Prostate carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
CYP3A43 and PARP2 variants have been shown to occur in other familial PCs and our findings add to the contribution that these variants potentially have in the risk and development of PC in BRCAX cases.
|
26585945 |
2016 |
|
Prostate carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Several SNPs (SRD5A1 rs3822430, SRD5A2 rs2300700, CYP3A43 rs800672, and CYP19 rs700519; Ptrend < .05) were significantly associated with both circulating hormone levels and prostate cancer risk.
|
27164191 |
2016 |
|
Prostate carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
|
25337833 |
2015 |
|
Prostate carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Four missense variants, BLM Gln123Arg, PARP2 Arg283Gln, LRCC46 Ala295Thr and KIF2B Pro91Leu, and one nonsense variant, CYP3A43 Arg441Ter, showed complete co-segregation with PCa status.
|
25111073 |
2014 |
|
Prostate carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the CYP3A43-Pro(340)Ala polymorphism contributes to prostate cancer risk.
|
15894682 |
2005 |
|
Prostate carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
CYP3A43*3 was associated with family history-positive prostate cancer (age- and race-adjusted odds ratio = 5.86, 95% confidence interval, 1.10-31.16).
|
15548719 |
2004 |
|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Subgroup analyses showed an association between the CYP3A43_74_delA allele and high-grade tumors (odds ratio, 1.74; 95% confidence interval, 1.14-2.65 [P=.010 and Ptrend=.012]).
|
20715157 |
2010 |
|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
After considering the potential for false positive associations, the only remaining significant associations involved CYP3A43 P340A genotypes and history of BPH on both Gleason grade (interaction p-value = 0.026) and tumor stage (interaction p-value = 0.017).
|
18566991 |
2008 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
No differences in genotype frequencies between cases and controls were observed, indicating that CYP3A43_74_delA is not associated with breast cancer risk.
|
20715157 |
2010 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
No differences in genotype frequencies between cases and controls were observed, indicating that CYP3A43_74_delA is not associated with breast cancer risk.
|
20715157 |
2010 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The frameshift polymorphism CYP3A43_74_delA is associated with poor differentiation of breast tumors.
|
20715157 |
2010 |
|
Benign Prostatic Hyperplasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
After considering the potential for false positive associations, the only remaining significant associations involved CYP3A43 P340A genotypes and history of BPH on both Gleason grade (interaction p-value = 0.026) and tumor stage (interaction p-value = 0.017).
|
18566991 |
2008 |